Mattias Hammarström 研究低剂量他莫昔芬和端氧苯酚用于乳腺癌预防
Q&A: Researcher investigates pharmacological approaches to breast cancer prevention
研究发现,低剂量他莫昔芬和低剂量端氧苯酚可能减少副作用同时仍影响健康女性的乳腺组织,有助于更个体化的乳腺癌预防策略。低剂量他莫昔芬与较少严重副作用相关,特别是在未进入更年期的女性中。端氧苯酚直接给药可减少乳腺密度,但较高剂量可能导致更多热潮红和夜间出汗。未来需进一步研究以验证其预防效果。
In a new thesis, Mattias Hammarström studied whether lower doses of tamoxifen and also its active metabolite endoxifen for direct administration, as a preventive medication could reduce side effects while still affecting breast tissue in healthy women. The findings suggest that lower doses of tamoxifen and a low dose of endoxifen may offer a better balance between biological effects and side effects, potentially contributing to more individualized approaches to breast cancer prevention.
Breast cancer is the most common cancer among women worldwide. Although treatments have improved, preventing breast cancer remains an important goal. Some women may benefit from preventive medication, but for healthy women, the potential benefits must be balanced against side effects.
Tamoxifen has been used to treat breast cancer for decades and can also reduce the risk of developing the disease. Endoxifen is considered one of the most active metabolites of tamoxifen and has not yet been evaluated as a new drug for breast cancer prevention. Tamoxifen and its metabolites block the effects of the hormone estrogen in breast tissue and thereby inhibit estrogen-driven cancer growth. However, side effects such as hot flashes and night sweats can discourage women from taking preventive treatment.
Mattias Hammarström is a project manager in the KARMA program and a Ph.D. student at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and his thesis includes four studies, based on two randomized, placebo-controlled clinical trials, the KARISMA trials, in healthy women treated for six months.
What have you done in your studies?
We investigated different doses of tamoxifen and endoxifen and examined side effects, treatment adherence and changes in mammographic breast density. We used breast density as a measure of treatment response. Some previous studies indicate a lower breast cancer risk if density declines during treatment, although it does not prove that a treatment prevents breast cancer.
What are the most important results in your thesis?
Lower doses of tamoxifen were associated with less severe side effects, particularly among women who had not reached menopause. In these women, low levels of endoxifen in the blood were also associated with reductions in breast density similar to those seen with the standard 20 mg dose of tamoxifen. My studies also showed that side effects can influence whether women continue taking preventive medication. We found that early worsening of symptoms such as hot flashes was associated with subsequent nonadherence to tamoxifen.
When endoxifen was given directly, both 1 mg and 2 mg reduced breast density compared with placebo. Women receiving 1 mg reported a similar symptom profile to those receiving placebo, while 2 mg was associated with more hot flashes and night sweats. Together, the findings support further research into lower-dose tamoxifen and low-dose endoxifen as possible ways to achieve better acceptance and uptake in primary breast cancer prevention in women with a high risk of breast cancer.
Why did you become interested in this topic?
Our research group has been working for more than 15 years to reduce the burden of breast cancer through prevention. Initially, I worked as a clinical trial manager, coordinating the practical aspects of our studies, including staff, study protocols, monitoring and trial operations. Later, I had the opportunity to become more involved in the scientific work through Ph.D. studies.
I share the vision of our entire research group: if we can prevent breast cancer before it develops, we can reduce both the suffering experienced by individuals and the costs to society. However, our goal should not be to offer preventive treatment to as many women as possible, but to identify those most likely to benefit, while carefully balancing the potential benefits and harms for each individual.
What do you think should be done in future health care and research?
The most important next step is to investigate whether lower doses of tamoxifen and oral endoxifen can also reduce breast cancer incidence. Our studies used mammographic breast density as a biomarker of treatment response. Although reductions in breast density are associated with lower breast cancer risk, we cannot conclude that the reductions observed in our studies translate into fewer breast cancers. Therefore, larger studies with long-term follow-up are needed to establish their preventive effectiveness.
More information
Mattias Hammarström, Tamoxifen and endoxifen in healthy women : dose, exposure, tolerability and mammographic breast density, (2026). DOI: 10.69622/33368287
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Q&A: Researcher investigates pharmacological approaches to breast cancer prevention (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-qa-pharmacological-approaches-breast-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com